| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
R-848 is a selective TLR8 agonist known for its ability to stimulate innate immune responses through precise receptor interactions. Its unique molecular configuration enables effective binding to TLR8, triggering a cascade of signaling events that enhance cytokine production. The compound's distinctive properties, including its stability and solubility, facilitate efficient cellular uptake and receptor engagement, promoting a swift immune activation process. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $157.00 $282.00 $516.00 $1177.00 $20138.00 $32779.00 $70753.00 | 1 | |
Gardiquimod is a potent TLR8 agonist that engages the immune system through specific molecular interactions, leading to the activation of various intracellular signaling pathways. Its unique structure allows for selective binding to TLR8, resulting in the modulation of gene expression related to immune responses. The compound exhibits favorable reaction kinetics, promoting rapid cellular responses and enhancing the overall efficacy of immune signaling. Its distinct physicochemical properties support effective receptor activation and downstream effects. | ||||||
CL097 | 1026249-18-2 | sc-507394 | 5 mg | $135.00 | ||
A synthetic imidazoquinoline compound that activates TLR8, promoting the production of TNF-α and other cytokines. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
A compound that specifically activates TLR8, initiating signal transduction pathways. | ||||||
Polyuridylic acid potassium salt | 27416-86-0 | sc-215733 sc-215733A | 10 mg 25 mg | $189.00 $343.00 | 2 | |
A synthetic RNA polymer, known to be a ligand for TLR8, stimulating immune response. | ||||||